Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters

Molecular Cancer Research

Volumn 5, Issue 7, 2007, Pages 749-759

  Wischnewski, Frank ^a   Friese, Olaf ^a   Pantel, Klaus ^a   Schwarzenbach, Heidi ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 12; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 2; TRANSCRIPTION FACTOR ETS 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME REPRESSION; FIBROBLAST; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN METHYLATION; UPREGULATION;

ANIMALS; ANTIGENS, NEOPLASM; CELL EXTRACTS; CELL LINE, TUMOR; CELL NUCLEUS; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; METHYL-CPG-BINDING PROTEIN 2; MICE; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEIN C-ETS-1; REPRESSOR PROTEINS; RNA SPLICING; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 34547096277     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0364     Document Type: Article

References (42)

1. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999;19:7327-35.
2. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001;61:5544-51.
3. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004;24:4781-90.
4. Inoue H, Li J, Honda M, et al. MAGE-1 mRNA expression in gastric carcinoma. Int J Cancer 1995;64:76-7.
5. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 2002;62:961-6.
6. Miyashiro I, Kuo C, Huynh K, et al. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin Chem 2001;47:505-12.
7. Otte M, Zafrakas M, Riethdorf L, et al. MAGE-A gene expression pattern in primary breast cancer. Cancer Res 2001;61:6682-7.
8. Kufer P, Zippelius A, Lutterbuse R, et al. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 2002;62:251-61.
9. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 1995;55:3478-82.
10. De Smet C, Courtois SJ, Faraoni I, et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 1995;42:282-90.
11. Sigalotti L, Fratta E, Coral S, et al. Intratumor heterogeneity of cancer/ testis antigens expression in human cutaneous melanoma is methylationregulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res 2004;64:9167-71.
12. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 1996;93:7149-53.
13. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
14. Sadanaga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001;7:2277-84.
15. Marchand M, Punt CJ, Aamdal S, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003;39:70-7.
16. Mischo A, Kubuschok B, Ertan K, et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 2006;118:696-703.
17. Nan X, Cross S, Bird A. Gene silencing by methyl-CpG-binding proteins. Novartis Found Symp 1998;214:6-16; discussion 16-21, 46-50.
18. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006;4:339-49.
19. Kondo E, Gu Z, Horii A, Fukushige S. The thymine DNA glycosylase MBD4 represses transcription and is associated with methylated p16(INK4a) and hMLH1 genes. Mol Cell Biol 2005;25:4388-96.
20. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 1998;18:6538-47.
21. Lewis JD, Meehan RR, Henzel WJ, et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992;69:905-14.
22. Weitzel JM, Buhrmester H, Stratling WH. Chicken MAR-binding protein ARBP is homologous to rat methyl-CpG-binding protein MeCP2. Mol Cell Biol 1997;17:5656-66.
23. Kaludov NK, Wolffe AP. MeCP2 driven transcriptional repression in vitro: selectivity for methylated DNA, action at a distance and contacts with the basal transcription machinery. Nucleic Acids Res 2000;28:1921-8.
24. Yu F, Thiesen J, Stratling WH. Histone deacetylase-independent transcriptional repression by methyl-CpG-binding protein 2. Nucleic Acids Res 2000;28:2201-6.
25. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001;27:322-6.
26. Jorgensen HF, Ben-Porath I, Bird AP. Mbd1 is recruited to both methylated and nonmethylated CpGs via distinct DNA binding domains. Mol Cell Biol 2004;24:3387-95.
27. Fujita N, Takebayashi S, Okumura K, et al. Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms. Mol Cell Biol 1999;19:6415-26.
28. Yu F, Zingler N, Schumann G, Stratling WH. Methyl-CpG-binding protein 2 represses LINE-1 expression and retrotransposition but not Alu transcription. Nucleic Acids Res 2001;29:4493-501.
29. Fujita H, Fujii R, Aratani S, Amano T, Fukamizu A, Nakajima T. Antithetic effects of MBD2a on gene regulation. Mol Cell Biol 2003;23:2645-57.
30. Ng HH, Zhang Y, Hendrich B, et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 1999;23:58-61.
31. Lembo F, Pero R, Angrisano T, et al. MBDin, a novel MBD2-interacting protein, relieves MBD2 repression potential and reactivates transcription from methylated promoters. Mol Cell Biol 2003;23:1656-65.
32. Zhao X, Ueba T, Christie BR, et al. Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc Natl Acad Sci U S A 2003;100:6777-82.
33. Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev 2001;15:710-23.
34. Cross SH, Meehan RR, Nan X, Bird A. A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins. Nat Genet 1997;16:256-9.
35. Majumder S, Kutay H, Datta J, Summers D, Jacob ST, Ghoshal K. Epigenetic regulation of metallothionein-i gene expression: differential regulation of methylated and unmethylated promoters by DNA methyltransferases and methyl CpG binding proteins. J Cell Biochem 2006;97:1300-16.
36. Wade PA. Methyl CpG-binding proteins and transcriptional repression. Bioessays 2001;23:1131-7.
37. Loriot A, De Plaen E, Boon T, De Smet C. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J Biol Chem 2006;281:10118-26.
38. Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem 2002;277:41571-9.
39. Jorgensen HF, Bird A. MeCP2 and other methyl-CpG binding proteins. Ment Retard Dev Disabil Res Rev 2002;8:87-93.
40. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
41. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196:1-7.
42. Schwarzenbach H, Newell JW, Matthias P. Involvement of the Ets family factor PU.1 in the activation of immunoglobulin promoters. J Biol Chem 1995;270:898-907.